CN116268525A - Nicotine salt, atomized liquid, cartridge and application thereof - Google Patents

Nicotine salt, atomized liquid, cartridge and application thereof Download PDF

Info

Publication number
CN116268525A
CN116268525A CN202211676114.9A CN202211676114A CN116268525A CN 116268525 A CN116268525 A CN 116268525A CN 202211676114 A CN202211676114 A CN 202211676114A CN 116268525 A CN116268525 A CN 116268525A
Authority
CN
China
Prior art keywords
nicotine
molar ratio
acid
lactic acid
nicotine salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211676114.9A
Other languages
Chinese (zh)
Inventor
邹阳
邹军
刘梅森
吕浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Zinwi Biotech Co Ltd
Original Assignee
Shenzhen Zinwi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Zinwi Biotech Co Ltd filed Critical Shenzhen Zinwi Biotech Co Ltd
Publication of CN116268525A publication Critical patent/CN116268525A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application provides a nicotine salt, wherein the nicotine salt is prepared from lactic acid, levulinic acid, or a combination thereof, and nicotine. The nicotine salt can make the sweetness of atomized liquid more outstanding, under the same sweet demand, will use less sweetener for the security is higher, and in this proportion within range, the sweetness of same quantity sweetener is felt more stably, can make the research and development or the better control sweetener's of production personnel use amount. In addition, the nicotine salts described herein, in certain ratio ranges, allow for lower amounts of nicotine and nicotine oxides, i.e., for a more stable nicotine salt system. The application also provides an atomized liquid containing the nicotine salt and a cartridge.

Description

Nicotine salt, atomized liquid, cartridge and application thereof
Technical Field
The application relates to the field of electronic cigarettes, in particular to nicotine salt, atomized liquid, a cartridge and application thereof.
Background
Nicotine, also known as nicotine, is an alkaloid present in plants of the Solanaceae family (Solanum), and is also an important component of tobacco. Nicotine and salt forms thereof are applied to electronic cigarette tar, and the electronic cigarette is used as one of cigarette substitutes, but the nicotine is easy to oxidize, so that the taste of the electronic cigarette tar is affected to a certain extent, and meanwhile, people inhale oxidative decomposition substances, so that organs are damaged to a certain extent. As more and more smokers use electronic cigarettes to replace cigarettes, the importance of nicotine salt safety is further reflected, and the requirements of the smokers on taste are higher, so that the safety and the taste become directions of exploration of electronic cigarette researchers.
At present, the nicotine benzoate cannot meet the requirements on taste and stability, so that a novel nicotine salt (nicotine salt) is needed to meet the requirements on different flavors and tastes and achieve better stability.
Disclosure of Invention
In order to solve the technical problems, the invention provides the nicotine salt with certain proportion, which can make the sweetness of the atomized liquid more outstanding, and under the same sweetness requirement, fewer sweeteners are used, so that the safety is higher, and in the proportion range, the sweetness of the same amount of sweetener is more stable, and the using amount of the sweetener can be better controlled by research personnel or production personnel. In addition, in the ratio range, it is possible to make the amount of nornicotine and nicotine nitrogen oxides smaller, i.e. to make the nicotine salt system more stable.
In particular, the method comprises the steps of,
in one aspect, the present invention provides a nicotine salt formulation wherein the nicotine salt is prepared from lactic acid and nicotine in a molar ratio of from (1.1-2): 1.
in some embodiments, the nicotine salt formulation further comprises ethyl butyrate, the mass fraction of ethyl butyrate is 0% -5%.
In some embodiments, the lactic acid to nicotine molar ratio is (1.1-2): 1; or (1.2-2): 1; or (1.3-2): 1; or (1.4-2): 1; or (1.5-2): 1; or (1.6-2): 1; or (1.7-2): 1; or (1.8-2): 1; or (1.9-2): 1; or 2:1; or (1.1-1.9): 1; or (1.2-1.9): 1; or (1.3-1.9): 1; or (1.4-1.9): 1; or (1.5-1.9): 1; or (1.6-1.9): 1; or (1.7-1.9): 1; or (1.8-1.9): 1; or 1.9:1; or (1.1-1.8): 1; or (1.2-1.8): 1; or (1.3-1.8): 1; or (1.4-1.8): 1; or (1.5-1.8): 1; or (1.6-1.8): 1; or (1.7-1.8): 1; or 1.8:1; or (1.1-1.7): 1; or (1.2-1.7): 1; or (1.3-1.7): 1; or (1.4-1.7): 1; or (1.5-1.7): 1; or (1.6-1.7): 1; or 1.7:1; or (1.1-1.6): 1; or (1.2-1.6): 1; or (1.3-1.6): 1; or (1.4-1.6): 1; or (1.5-1.6): 1; or 1.6:1; or (1.1-1.5): 1; or (1.2-1.5): 1; or (1.3-1.5): 1; or (1.4-1.5): 1; or 1.5:1; or (1.1-1.4): 1; or (1.2-1.4): 1; or (1.3-1.4): 1; or 1.4:1; or (1.1-1.3): 1; or (1.2-1.3): 1; or 1.3:1; or (1.1-1.2): 1; or 1.2:1; or 1.1:1.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, 1, 2-propanediol, 1, 3-propanediol, glycerol.
In another aspect, the invention also provides an electronic atomized liquid which contains the nicotine salt preparation.
In some embodiments, the nicotine in the nicotine salt formulation has a concentration in the electrospray liquid of greater than 0% w/w, less than 10% w/w.
In some embodiments, the electrospray liquid further comprises one or more of a sweetener, a cooling agent, and a flavor.
On the other hand, the invention also provides an electronic cigarette cartridge which comprises the electronic atomization liquid.
In some embodiments, the electronic cigarette cartridge further comprises an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
In some embodiments, the electronic cartomizer further comprises a heating element that atomizes the electronic aerosol by heating.
In some embodiments, the electronic cigarette cartridge further comprises an ultrasonic wave generating element for atomizing the electronic atomized liquid by ultrasonic waves.
In order to solve the technical problems, the invention also provides a nicotine salt preparation, wherein the nicotine salt is prepared from organic acid and nicotine, and the organic acid consists of levulinic acid and lactic acid.
In particular, the method comprises the steps of,
in one aspect, the present invention provides a nicotine salt formulation, wherein the nicotine salt is prepared from an organic acid and nicotine, said organic acid consisting of levulinic acid and lactic acid, said levulinic acid to lactic acid molar ratio being from 12:1 to 1:1; the molar ratio of the organic acid to nicotine is from 0.6:1 to 2:1.
In some embodiments, the nicotine salt formulation further comprises ethyl butyrate, the mass fraction of ethyl butyrate is 0% -5%.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (12-1): 1, (11-1): 1, (10-1): 1, (9-1): 1, (8-1): 1, (7-1): 1, (6-1): 1, (5-1): 1, (4-1): 1, (3-1): 1, (2-1): 1 or 1:1. The molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, 1, 2-propanediol, 1, 3-propanediol, glycerol.
In another aspect, the invention also provides an electronic atomized liquid containing the nicotine salt preparation.
In some embodiments, the nicotine in the nicotine salt formulation has a concentration in the electrospray liquid of greater than 0% w/w, less than 10% w/w.
In some embodiments, the electrospray liquid further comprises one or more of a sweetener, a cooling agent, and a flavor.
On the other hand, the invention also provides an electronic cigarette cartridge which comprises the electronic atomization liquid.
In some embodiments, the electronic cigarette cartridge further comprises an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
In some embodiments, the electronic cartomizer further comprises a heating element that atomizes the electronic aerosol by heating.
In some embodiments, the electronic cigarette cartridge further comprises an ultrasonic wave generating element for atomizing the electronic atomized liquid by ultrasonic waves.
In order to solve the technical problem, the invention also provides a nicotine salt preparation, wherein the nicotine salt is prepared from levulinic acid and nicotine.
In particular, the method comprises the steps of,
in one aspect, the present invention provides a nicotine salt formulation wherein the nicotine salt is prepared from levulinic acid and nicotine in a molar ratio of levulinic acid to nicotine of from 0.4:1 to 0.9:1.
in some embodiments, the nicotine salt formulation further comprises ethyl butyrate, the mass fraction of ethyl butyrate is 0% -5%.
In some embodiments, wherein the molar ratio of levulinic acid to nicotine is (0.4-0.9): 1; or (0.5-0.9): 1; or (0.6-0.9): 1; or (0.7-0.9): 1; or (0.8-0.9): 1; or 0.9:1; or (0.4-0.8): 1; or (0.5-0.8): 1; or (0.6-0.8): 1; or (0.7-0.8): 1; or 0.8:1; or (0.4-0.7): 1; or (0.5-0.7): 1; or (0.6-0.7): 1; or 0.7:1; or (0.4-0.6): 1; or (0.5-0.6): 1; or 0.6:1; or (0.4-0.5): 1; or 0.5:1; or 0.4:1.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
In some embodiments, the nicotine salt formulation further comprises a solvent that is one or more of water, 1, 2-propanediol, 1, 3-propanediol, glycerol.
In another aspect, the invention also provides an electronic atomized liquid which contains the nicotine salt preparation.
In some embodiments, the nicotine in the nicotine salt formulation has a concentration in the electrospray liquid of greater than 0% w/w, less than 10% w/w.
In some embodiments, the electrospray liquid further comprises one or more of a sweetener, a cooling agent, and a flavor.
On the other hand, the invention also provides an electronic cigarette cartridge which comprises the electronic atomization liquid.
In some embodiments, the electronic cigarette cartridge further comprises an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
In some embodiments, the electronic cartomizer further comprises a heating element that atomizes the electronic aerosol by heating.
In some embodiments, the electronic cigarette cartridge further comprises an ultrasonic wave generating element for atomizing the electronic atomized liquid by ultrasonic waves.
On the other hand, the invention also provides the application of the nicotine salt in the tobacco, fruit or flower electronic atomization liquid
On the other hand, the invention also provides application of the nicotine salt in the tobacco aroma electronic atomized liquid.
On the other hand, the invention also provides the application of the nicotine salt in the fruit-flavored electronic atomized liquid.
On the other hand, the invention also provides application of the nicotine salt in the floral electronic atomized liquid.
Detailed description
For the purposes of the following detailed description, it is to be understood that the application may assume various alternative variations and step sequences, except where expressly specified to the contrary. Furthermore, except in any operating examples, or where otherwise indicated, all numbers expressing, for example, quantities of ingredients used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present application. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Nicotine, also known as nicotine, is an alkaloid present in plants of the Solanaceae family (Solanum), and is also an important component of tobacco. Nicotine and salt forms thereof are applied to electronic cigarette tar, and the electronic cigarette is used as one of cigarette substitutes, but the nicotine is easy to oxidize, so that the taste of the electronic cigarette tar is affected to a certain extent, and meanwhile, people inhale oxidative decomposition substances, so that organs are damaged to a certain extent. As more and more smokers use electronic cigarettes to replace cigarettes, the importance of nicotine salt safety is further reflected, and the requirements of the smokers on taste are higher, so that the safety and the taste become directions of exploration of electronic cigarette researchers.
Many studies report the effect of nicotine absorption, nicotine irritation after nicotine protonation, and thus the smoker experience, and the inventors have found that different acids, which have similar degrees of nicotine protonation, can lead to differences in mouthfeel and stability with certain amounts or ratios.
Figure SMS_1
Further, the inventors have unexpectedly found that some acids, such as lactic acid, levulinic acid, or mixed acids of lactic acid and levulinic acid, using nicotine salts prepared in certain amounts or proportions have different effects on the mouthfeel produced by atomization of different flavored e-cigarette atomized liquids, presumably due to different chemical structures of the different acids, molecular forces between the nicotine liquid preparation and other components are different, so that the e-cigarette has different atomization effects and different coordination effects among the components during smoking.
Further, the inventors have unexpectedly found that some acids, such as lactic acid, levulinic acid, or mixed acid of lactic acid and levulinic acid, adopt nicotine salts prepared by certain content or proportion, have different effects on the sweetness generated by atomization of the atomized liquid of the electronic cigarette, namely, the sweetness is different when the content of the sweetener is the same, and the detection study is carried out on a plurality of components such as sweetener, solvent and the like in the atomized aerosol, so that the atomization efficiency of the solvent is presumably changed due to different chemical structures of different acids, such as different proportions used in the atomized liquid of the electronic cigarette, which may have certain effects on the formation of hydrogen bonds among molecules of the solvent.
Further, the inventors have unexpectedly found that certain acids, such as lactic acid, levulinic acid, or a mixture of lactic acid and levulinic acid, have a differential effect on the stability of nicotine when nicotine salts are prepared, particularly on the change of oxides or decomposers of nicotine which are more harmful to humans, presumably by the fact that they form salts with nicotine, not only proton donors, but also by the effect of the structure or ratio of these acids, form a combination of different stabilities with nicotine, and that some make nicotine more stable and less susceptible to oxidation or decomposition. In particular, it is advantageous to control carcinogens in e-cigarettes, such as nornicotine, for example.
The inventors have unexpectedly found that when lactic acid, levulinic acid or a mixed acid thereof is added to nicotine in a certain ratio to prepare a nicotine salt, there is a phenomenon that stability and taste are simultaneously satisfied; there is no correlation between mouthfeel and stability.
In one aspect, the present inventors have discovered a nicotine salt formulation wherein the nicotine salt is prepared from lactic acid and nicotine in a molar ratio of from 1.1:1 to 2:1, there is a phenomenon that stability and mouthfeel are simultaneously satisfied.
Lactic acid has a structural formula (A), a 3D diagram of a molecular structure of the lactic acid is shown in figure 1, and the lactic acid contains hydroxyl and belongs to alpha-hydroxy acid (AHA). Lactic acid had a density of 1.209 (g/mL, 25 ℃) and a boiling point of 122 ℃ (15 mmHg), dissociation constant pka=4.14 (22.5 ℃). Lactic acid is widely existing in human body, animals, plants and microorganisms, and the current lactic acid is produced by adopting a biological fermentation method, so that the lactic acid has higher safety.
Figure SMS_2
When the molar ratio of lactic acid to nicotine is from 1.1:1 to 2:1, can let the sweetness of atomized liquid more outstanding, under the same sweet demand, will use less sweetener for the security is higher, and in this proportion within range, the sweetness of same quantity sweetener is felt more stably, can make the use amount of research and development or production personnel better control sweetener. In addition, in the ratio range, it is possible to make the amount of nornicotine and nicotine nitrogen oxides smaller, i.e. to make the nicotine salt system more stable.
In some embodiments, the lactic acid to nicotine molar ratio is (1.1-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.5-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.6-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.7-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.8-2): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.9-2): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 2:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.5-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.6-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.7-1.9): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.8-1.9): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.9:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.5-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.6-1.8): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.7-1.8): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.8:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.7): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.7): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.7): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-1.7): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.5-1.7): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.6-1.7): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.7:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.6): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.6): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.6): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-1.6): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.5-1.6): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.6:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.5): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.5): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.5): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.4-1.5): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.5:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.4): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.4): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.3-1.4): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.4:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.3): 1; in some embodiments, the lactic acid to nicotine molar ratio is (1.2-1.3): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.3:1; in some embodiments, the lactic acid to nicotine molar ratio is (1.1-1.2): 1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.2:1; in some embodiments, the molar ratio of lactic acid to nicotine is 1.1:1.
In one aspect, the present inventors have discovered a nicotine salt formulation wherein the nicotine salt is prepared from levulinic acid and nicotine in a molar ratio of levulinic acid to nicotine of from 0.4:1 to 0.9:1, there is a phenomenon that stability and mouthfeel are simultaneously satisfied.
Levulinic acid, having structural formula (B), whose molecular structure 3D is shown in fig. 2, is a ketocarboxylic acid having a ketocarbonyl group. Levulinic acid has a density of 1.134 (g/mL, 25 ℃) and a boiling point of 245-246 ℃, dissociation constant pka=4.65 (25 ℃). Levulinic acid can be prepared by pressurized hydrolysis of residues (furfural residues) or waste sweet potato residues after the production of furfural by cotton seed hulls or corncobs with dilute acid.
Figure SMS_3
When the molar ratio of levulinic acid to nicotine is from 0.4:1 to 0.9:1, which has a modifying effect on the tobacco-flavored electronic atomized liquid. In addition, in the ratio range, it is possible to make the amount of nornicotine and nicotine nitrogen oxides smaller, i.e. to make the nicotine salt system more stable.
In some embodiments, the levulinic acid to nicotine molar ratio is (0.4-0.9): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.5-0.9): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.6-0.9): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.7-0.9): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.8-0.9): 1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.9:1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.4-0.8): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.5-0.8): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.6-0.8): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.7-0.8): 1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.8:1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.4-0.7): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.5-0.7): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.6-0.7): 1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.7:1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.4-0.6): 1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.5-0.6): 1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.6:1; in some embodiments, the levulinic acid to nicotine molar ratio is (0.4-0.5): 1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.5:1; in some embodiments, the molar ratio of levulinic acid to nicotine is 0.4:1.
In one aspect, the present inventors have found a nicotine salt formulation wherein the nicotine salt is prepared from an organic acid and nicotine, the organic acid consisting of levulinic acid and lactic acid, the molar ratio of levulinic acid to lactic acid being from 12:1 to 1:1, a step of; the molar ratio of the organic acid to nicotine is from 0.6:1 to 2:1.
when the levulinic acid to lactic acid molar ratio is from 12:1 to 1:1, a step of; the molar ratio of the organic acid to nicotine is from 0.6:1 to 2:1, the sweetness of the atomized liquid can be more prominent, and less sweetener is used under the same sweetness requirement, so that the safety is higher.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (12-1): 1, (11-1): 1, (10-1): 1, (9-1): 1, (8-1): 1, (7-1): 1, (6-1): 1, (5-1): 1, (4-1): 1, (3-1): 1, (2-1): 1, or 1:1.
In some embodiments, the levulinic acid to lactic acid molar ratio is 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, or 1:1.
In some embodiments, the molar ratio of organic acid to nicotine is (0.6-2): 1, (0.7-2): 1, (0.8-2) 1, (0.9-2) 1, (1.1-2) 1, (1.2-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1.1.9) 1, (1.9-1.9) 1, (1.3-1.9) 1, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.8-1.9) 1, 1.9, (0.6-1.9) 1, (0.8-1.9) 1.1.9) 1, (1.8-8) 1.9) 1 and (1.9) (1.4-1.8): 1, (1.5-1.8): 1, (1.6-1.8): 1.7-1.8) 1.1.8:1.0.6-1.7, (0.7-1.7) 1, (0.8-1.7) 1, (0.9-1.7) 1, (1-1.7) 1, (1.1-1.7) 1, (1.2-1.7) 1, (1.3-1.7) 1, (1.4-1.7) 1, (1.5-1.7) 1, (1.6-1.7) 1, 1.7:1, (0.6-1.6) 1, (0.9-1.6) 1, (0.8-1.6) 1, (1.9-1.6) 1, (1.1-1.6) 1, (1.3-1.6) 1, 1.1-1.6, 1.6-1.6) 1, (1.1.1-1.6, 1.6-1.1.6) 1, (1.5-1.6) 1, (1.5-5.6) 1, (1.5-5, and (1.5-5) 1.6) 1.5-5, and (0.5-1.6) 1.6 (0.9-1.4): 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, (0.8-1.1): 1, (0.1.1.1): 1, (1.3-1): 1.3): 1, (1.1) 1, 1.1:1, (1.3-1.3): 1, 1.1): 1, (0.1.2): 1.1): 1, (1.1.1): 1.1): 1, (1.2): 1.1, (1.1): 1.1.1): 1.1.1.1): 1.1.1): 1.1.1.1.1.1): 1.1.1 1.1 1) 11 1.
In some embodiments, the molar ratio of the organic acid to nicotine is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (12-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (11-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (10-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (9-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (8-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (7-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (6-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (5-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (4-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (3-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is (2-1): 1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid to lactic acid molar ratio is 1:1; the molar ratio of the organic acid to the nicotine is 0.6-2:1, (0.7-2:1, (0.8-2) 1, (0.9-2) 1, (1-2) 1, (1.1-2) 1, (1.3-2) 1, (1.4-2) 1, (1.5-2) 1, (1.6-2) 1, (1.7-2) 1, (1.8-2) 1, (1.9-2) 1, 2:1, (0.6-1.9) 1, (0.7-1.9) 1, (0.8-1.9) 1, (0.9-1.9) 1, (1-1.9) 1, (1.1-1.9) 1-1.9, (1.3-1.9) 1.9, (1.4-1.9) 1, (1.5-1.9) 1, (1.6-1.9) 1, (1.7-1.9) 1, (1.8) 1.9 and (1.8-1.9) 1.1 and (1.8-8) 1.9) (1.5-1.8): 1, (1.6-1.8): 1, (1.7-1.8): 1.8:1, (0.6-1.7): 1, (0.7-1.7): 1, (0.8-1.7): 1, (0.9-1.7): 1, (1.1-1.7): 1, (1.2-1.7): 1, (1.3-1.7): 1, (1.4-1.7): 1, (1.5-1.7): 1, (1.6-1.7): 1, 1.7:1, (0.6-1.6): 1, (0.7-1.6): 1, (0.8-1.6): 1, (0.9-1.6): 1, (1.1-1.6): 1, (1.1.1-1.6): 1, (1.1.4-1.6): 1, 1.6:1.1, 1.6:1, (1.5-1.6): 1, (1.5): 1, (1.5): 1.6): 1, (1.5): 1, (1.6): 1, 1.6) 1.6, and, (0.6-1.6): 1.6) 1.6, 1.6 and (1.6) 1.6, 1.6 1 1.6 1, (1-1.4): 1, (1.1-1.4): 1, (1.2-1.4): 1, (1.3-1.4): 1, 1.4:1, (0.6-1.3): 1, (0.7-1.3): 1, (0.8-1.3): 1, (0.9-1.3): 1, (1.1-1.3): 1, (1.2-1.3): 1, 1.3:1, (0.6-1.2): 1, (0.7-1.2): 1, (0.8-1.2): 1, (0.9-1.2): 1, (1-1.2): 1, (1.1-1.2): 1, 1.2:1, (0.6-1.1): 1, (0.1.1.1): 1, (0.1-1.1.1): 1, (1.1.1.1-1.1.1): 1, (1.1, (1.3): 1.1.1-1.3): 1, 1.1, 1.3): 1, (1.1.1, 1.1): 1.1, 1.2): 1.1, 1.1.1, 1.1 (1.1.1.1, 1.1, 1.1.1, 1.1 1, 1.
In some embodiments, the levulinic acid-to-lactic acid molar ratio is 12:1, the molar ratio of the organic acid to nicotine is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1 or 2:1; in some embodiments, the levulinic acid-to-lactic acid molar ratio is 11:1, the organic acid-to-nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 10:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 9:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 8:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 7:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 6:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 5:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 4:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 3:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid to lactic acid molar ratio is 2:1, the organic acid to nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1; in some embodiments, the levulinic acid-to-lactic acid molar ratio is 1:1, and the organic acid-to-nicotine molar ratio is 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, or 2:1.
In another aspect, the nicotine salt formulation of the present invention further comprises a solvent, wherein the solvent is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, and 1,2, 4-butanetriol. The solvent is not a requirement for protonation of nicotine, but in some embodiments, the solvent is capable of promoting the protonation process. In some embodiments the solvent is one or more of water, 1, 2-propanediol, 1, 3-propanediol, glycerol. In some embodiments the solvent is one or more of water, 1, 2-propanediol, or a combination thereof. In some embodiments the solvent is one or more of 1, 2-propanediol, glycerol, or a combination thereof.
In some embodiments, the solvent is present in the electrospray liquid in a mass fraction of 20% -90%; in some embodiments, the solvent is present in the electrospray liquid in a mass fraction of 30% -80%. In some embodiments, the mass fraction of 1, 2-propanediol in the electrospray liquid is from 0% to 30%; in some embodiments, the mass fraction of glycerol in the electrospray liquid is 30% -50%. In some embodiments, the mass fraction of 1, 2-propanediol in the electrospray liquid is 20% to 60%; in some embodiments, the mass fraction of glycerol in the electrospray liquid is 40% -80%.
On the other hand, the inventor finds that the electronic atomized liquid prepared by adopting the nicotine salt preparation provided by the invention has the advantage of nicotine salt. In some embodiments, the nicotine in the nicotine salt formulation has a concentration in the electrospray liquid of greater than 0% w/w, less than 10% w/w. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 1% w/w to 9% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 1% w/w to 8% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 1% w/w to 7% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 1% w/w to 6% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 1% w/w to 5% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 1% w/w to 4% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 1% w/w to 3% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 1% w/w to 2% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 1% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 2% w/w to 5% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 2% w/w to 4% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 2% w/w to 3% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 2% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 3% w/w to 5% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 3% w/w to 4% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 3% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 4% w/w to 5% w/w in the electrospray liquid. The nicotine in the nicotine salt formulation has a concentration of 4% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 5% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 6% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 7% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 8% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 9% w/w in the electrospray liquid. In some embodiments, the nicotine in the nicotine salt formulation has a concentration of 10% w/w in the electrospray liquid.
In another aspect, the electrospray liquid further comprises one or more of a sweetener, a cooling agent, and a flavoring.
Sweeteners, cooling agents and flavors refer to materials that can be used to produce a desired taste or aroma in an adult consumer product, as permitted by local regulations. They may include extracts (e.g., licorice, hydrangea, japanese white magnolia leaf, chamomile, fenugreek, clove, menthol, japanese mint, star anise, cinnamon, vanilla, holly, cherry, berry, peach, apple, du Linbiao (dragambue), boy, scotch whiskey, spearmint, peppermint, lavender, cardamom, celery, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla essence, lemon oil, orange oil, cinnamon, carvedilol, brandy, waxberry, ylang, sage, multi-spice, ginger, fennel, coriander, coffee, or peppermint oil from any species of the genus mentha), flavor enhancers, bitter taste receptor site blockers or stimulators, sugars and/or sugar substitutes (e.g., neotame, sucralose, acesulfame potassium, aspartame, saccharin, cyclamate, sucrose, sorbitol, mannitol, or other plant or mineral additives (e.g., fruit), fresh air, charcoal or other products). They may be imitation, synthetic or natural ingredients or mixtures thereof. They may be in any suitable form, for example, oil, liquid or powder. The amounts of sweetener, cooling agent and flavoring are generally in accordance with national standards.
In some embodiments, the sweetener comprises one or more of neotame, cyclamate, sucralose, alitame, aspartame, sodium saccharin, acesulfame, ammonium glycyrrhizinate, thaumatin, stevioside, xylitol, maltose, stevioside, rhamnose, trehalose, erythritol, lactose, and galactose.
In some embodiments, the sweetener has a concentration of 0% -10% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -9% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -8% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -7% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -6% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -5% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -4% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -3% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -2% w/w in the electrospray liquid; in some embodiments, the sweetener has a concentration of 0% -1% w/w in the electrospray liquid.
In some embodiments, the cooling agent comprises one or more of peppermint oil, menthol, WS-23, L-menthone, menthyl acetate, menthyl lactate, WS-3, menthone glycerol ketal.
In some embodiments, the cooling agent has a concentration of 0% -10% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -9% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -8% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -7% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -6% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -5% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -4% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -3% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -2% w/w in the electrospray liquid; in some embodiments, the cooling agent has a concentration of 0% -1% w/w in the electrospray liquid.
In some embodiments, the perfume compound is selected from the group consisting of 1, 4-cineole, 1, 8-cineole, 2, 3-pentanedione, 2-methylpyrazine, 2-methoxy-3-methylpyrazine, 2-ethyl-3-methylpyrazine, 2-acetylpyrazine, 3-carene, 5-methylfurfural, alpha-pinene, beta-pinene, alpha-phellandrene, alpha-terpinol, myrcene, gamma-nonolactone, gamma-terpinene, butyric acid, ethyl butyrate, butyl butyrylactoate, 1-p-wagon
Figure SMS_4
One or more of alkene-8-mercaptan, methyl dihydrojasmonate, 3, 4-dimethoxybenzaldehyde, citral, triethyl citrate, ethyl nonanoate, glyceryl triacetate, vanillin, heliotropin, ethyl vanillin, acetoin, 2-methylbutyl acetate, ethyl acetate, isoamyl acetate, and isovaleraldehyde.
In some embodiments, the flavor is a fruit flavor, a floral flavor, or a tobacco flavor.
In some embodiments, the perfume has a concentration of 0% -50% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 0% -40% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 0% -30% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 0% -20% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 0% -10% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 10% -50% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 10% -40% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 10% -30% w/w in the electrospray liquid; in some embodiments, the perfume has a concentration of 10% -20% w/w in the electrospray liquid.
In some embodiments of the invention, the nicotine salt formulation or electrospray liquid comprises ethyl butyrate (formula C). Ethyl butyrate molecular weight 116.158; the boiling point was 122.4 ℃. Ethyl butyrate may be used as a perfume ligand, but there is no evidence that it can adjust the particle size of the electronically atomized aerosol of the nicotine salt formulation (lactate nicotine salt, levulinate nicotine salt, lactate+levulinate complex nicotine salt) described in the present invention.
Figure SMS_5
The ethyl butyrate is added into the nicotine salt preparation or the electronic atomized liquid, so that the concentration of small-particle-size particles in aerosol produced by the nicotine preparation or the electronic atomized liquid is reduced, the amount of aerosol deposited on alveoli is reduced, and the safety of the electronic atomized liquid is improved. In some embodiments, the ethyl butyrate is present in an amount of about greater than 0% (w/w) to less than 5% (w/w); in some embodiments, the ethyl butyrate is present in an amount of about greater than 0.02% (w/w) to less than 2% (w/w); in some embodiments, the ethyl butyrate is present in an amount of about greater than 0.1% (w/w) to less than 1% (w/w); in some embodiments, the ethyl butyrate is present in an amount of about 0.2% (w/w), 0.3% (w/w) 0.4% (w/w), 0.5% (w/w), 0.6% (w/w), or 0.7% (w/w).
On the other hand, the invention provides an electronic cigarette cartridge which comprises the electronic atomization liquid.
In some embodiments, the electronic cartridge includes a heating element that atomizes the electronic aerosol by heating. Atomizing cores in some embodiments, cotton cores are employed; atomizing cores ceramic cores are employed in some embodiments. In some embodiments, the electronic cartomizer includes an ultrasonic wave generating element through which the electronic aerosol is atomized.
The nicotine lactate salt atomizing liquid has good sucking taste, purer smoke and good stability. The atomized liquid of the levulinic acid nicotine salt has good suction taste, comfortable sour and sweet feel and can better keep the fragrance of cigarettes. The levulinic acid and lactic acid composite salt has good sucking taste, is rich in special fruit acid flavor, and can give out sweet and moist feeling.
In the present invention, the term "n-m" is used to denote a range of values, i.e., the range of numbers n to m, and in some embodiments the term "n-m" includes n, m, and all numbers between n and m. In other embodiments the range "n-m" includes m and all numbers between n and m; in some embodiments the range "n-m" includes n and all numbers between n and m; in some embodiments the range "n-m" includes all numbers between n and m.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
The articles "a," "an," and "the" are intended to include "at least one" or "one or more" unless the context clearly dictates otherwise or otherwise. Thus, as used herein, these articles refer to one or to more than one (i.e., to at least one) object. For example, "a component" refers to one or more components, i.e., more than one component is contemplated as being employed or used in embodiments of the described embodiments.
The present invention uses the following methods to test the content of neotame and 1,2 propanediol, glycerol, unless otherwise indicated or where there is a clear conflict in context.
The test method of neotame content in aerosol comprises the following steps:
1. sample collection
And (3) pumping according to the flow of the appendix C.5-C.7 of T/CECC001-2021, pumping a 50 port, transferring the filter membrane into a 50mL centrifuge tube after pumping, taking 10mL neotame extract (2.1.2) to fix the volume, performing ultrasonic treatment for 15min, shaking uniformly, filtering the 0.22um filter membrane, and performing on-machine analysis.
2. Measurement of samples
Determination of neotame in food according to national standard GB 5009.247-2016: after the sample is diluted and extracted, the sample is filtered and then is quantified by an external standard method, the capacity recovery rate of the neotame content in the electronic atomization liquid is between 95.07% and 104.94%, the RSD is less than 5%, and the measurement results are all in an index range and can meet the actual detection requirement.
The GC-FID method is used for measuring the content of 1, 2-propanediol and glycerol in the aerosol:
1. principle of
The method uses a gas chromatograph equipped with a hydrogen flame ionization detector to measure 1, 2-propanediol and glycerol in the diluent, and the external standard method is used for quantification.
2. Apparatus and device
2.1 gas chromatograph: shimadzu GC-2030; .
2.2 capillary chromatography column: DB-WAX,30 mX0.25 mm X0.25 μm;
2.3 electronic balance (weighing accuracy 0.0001 g);
2.4 general glassware.
3. Reagent and consumable
3.1 methanol- - - -chromatographic purity;
3.21,2-propylene glycol- -the purity is more than or equal to 99.5 percent and the propylene glycol should be stored in a dryer;
3.3 glycerol- -the purity is more than or equal to 99.5 percent and the glycerol should be stored in a dryer;
4. analytical procedure
4.1 preparation of solutions
4.1.1 Standard stock solution
1g of (3.2) 1, 2-propanediol and 1g of (3.3) glycerol are respectively weighed and placed into a 50ml volumetric flask, methanol (3.1) is used for constant volume to obtain standard stock solution of 1, 2-propanediol and glycerol with the concentration of 20mg/ml, and the stock solution is placed into a condition of 2-8 ℃ for sealing and preservation, and the effective period is 3 months. The product should be equilibrated to room temperature.
4.1.2 preparation of Standard working solution
Taking 5 volumetric flasks of 10mL, precisely transferring 0.05mL, 0.25mL, 0.5mL, 1mL and 2.5mL of standard solution (4.1.1) into the volumetric flasks of 10mL, and then using (3.1) methanol to fix the volume to obtain 5-grade standard working solution, wherein the standard working solution is prepared and used at present, and the details are shown in Table 1;
table 1: preparation of standard working solution
Level of STD1 STD2 STD3 STD4 STD5
Transfer volume (mL) 0.05 0.25 0.5 1 2.5
1, 2-propanediol (mg/ml) 0.1 0.5 1 2 5
Glycerol (mg/ml) 0.1 0.5 1 2 5
4.2 gas chromatograph conditions, see Table 2 for details:
table 2: gas chromatography conditions
Figure SMS_6
4.3 working Curve drawing
The chromatographic determination is carried out on the 1-5-grade standard solution according to the 4.2 gas chromatographic condition, and the sample injection amount is 1 mu L. Taking the peak area of the target compound and the peak area of the internal standard as the ordinate, The concentration of the target compound and the concentration of the internal standard are taken as abscissa, a standard working curve is established, and a linear correlation coefficient R 2 Should be greater than 0.999.
After each 20 samples are measured, a standard working solution with medium concentration is added, and if the measured value is different from the original value by more than 5%, the standard working curve is prepared again.
4.4 sample analysis
4.4.1 collection of samples
After the suction of the appendix C.5-C.7 of the T/CECC001-2021 is finished, sucking the 50 ports, taking out the filter disc with the atomized gas, wiping the inner wall of the catcher by a new filter disc with the thickness of 44mm, putting the catcher into a 50mL conical flask or a flask with a screw, accurately adding 20mL methanol solution, oscillating and extracting for 20min, and standing for later use.
4.4.2 blank test
The procedure of 4.4.1 was repeated without adding sample, and a blank test was performed. Typically, a blank test is required every 10 samples tested.
4.4.3 sample measurement
The test sample and the blank sample were tested by a gas chromatograph (2.1) under the test conditions of (4.2), and if the concentration of the test sample exceeded the range of the standard working curve, the dilution ratio was adjusted and the measurement was performed again.
5. Calculation and expression of results
5.1 calculation of target Compound content
The target content w in the sample is calculated in mg/g according to formula (1):
Figure SMS_7
Wherein:
w-content of target compound, mg/g
V-constant volume, mL
C 1 Instrument test results, mg/mL
C 0 Blank test results, mg/mL
d-dilution factor
M-sample weight, g
6. Quality assurance and control
6.1 quality control solution
The solution concentration same as the grade 3 standard curve is prepared as a quality control solution, the quality control solution is measured before sample detection every day, the recovery rate is ensured to be 93% -105%, and if the recovery rate exceeds a limit value, the standard curve solution needs to be prepared again.
If the number of samples to be tested exceeds 20 on the same day, a medium-concentration quality control solution is added after 20 sample measurements are carried out, and if the measured value differs from the original value by more than 5%, the whole standard working curve is produced again.
6.2 repeatability
The absolute difference between the two independent measurements obtained under repetitive conditions does not exceed 5% of the arithmetic mean.
Unless otherwise indicated or clear conflict exists in context, the present invention employs LC-MSMS to determine the levels of nornicotine and nicotine oxynitride in a nicotine formulation (external standard method):
1. reagent and Standard solution
1.1 reagents used:
1.1.1. acetonitrile (chromatographic purity)
1.1.2. Ammonia water (chromatographic purity)
1.1.3. Ultrapure water
1.1.4. Standard substance: reducing nicotine and nicotine nitrogen oxides
1.1.5 aqueous phase filtration membrane: 0.22um
1.2 reagent configuration
1.2.1 mobile phase A: 500mL of water (1.1.3) was measured, and 0.5mL of aqueous ammonia (1.1.2) was added to the mixture to obtain mobile phase A (0.1% aqueous ammonia).
1.2.2 mobile phase B: acetonitrile (1.1.1).
1.3 preparation of Standard solution
1.3.1 Single standard stock solution: the standard (1.1.4) was dissolved in acetonitrile (1.1.1) to prepare a single standard stock solution, typically 10mg/mL. -18 ℃ for storage, the effective period is 6 months;
1.3.2 mixing standard stock solution: each single standard stock solution (1.3.1) was accurately removed and a mixed standard stock solution, typically 0.1mg/mL, was prepared from acetonitrile (1.1.1). Storing at 4deg.C, and storing for 3 months;
1.3.3 standard working solution. The mixed standard stock solutions (1.3.2) with different volumes are removed in a 10mL volumetric flask, and the volume is fixed to the scale with water (1.1.3) to prepare at least 6 standard working solutions. The mass concentration range is preferably 0.001 to 0.2ug/mL. (for the present preparation)
2. Sample processing
Weighing 0.40g of nicotine preparation in a 10mL volumetric flask, fixing volume with aqueous solution (1.1.3), performing ultrasound for 5min, filtering with an aqueous phase filter membrane (1.1.5), and diluting with aqueous solution 2000 times that of chromatographic flask to be tested.
3. Instrument condition parameters
3.2 instrument conditions
3.2.1 liquid chromatography conditions
Chromatographic column: BEHC18column: (1.7 μm, 100X 2.1 mm) or equivalent columns;
mobile phase a (2.2.1): 0.1% aqueous ammonia solution;
mobile phase B (2.2.2): acetonitrile;
-column oven: 40 ℃;
column flow rate: 0.4mL/min;
sample volume: 5.0. Mu.L;
-run time: 8.0min;
-elution gradient: gradient elution is shown in table 3.
TABLE 3 elution gradient
Time Flow rate (ml/min) ％A ％B Curve
Initiation 0.400 97.0 3.0 Initiation
0.5 0.400 97.0 3.0 6
1.00 0.400 75.0 25.0 6
5.00 0.400 50.0 50.0 6
5.10 0.400 10.0 90.0 6
6.00 0.400 10.0 90.0 6
6.10 0.400 97.0 3.0 6
8.00 0.400 97.0 3.0 6
3.2.2 Mass Spectrometry conditions
-ion source: electrospray ion source (esi+);
ionization mode: a positive ion mode;
electrospray voltage: 1.5KV;
ion source temperature, desolventizing temperature: 150 ℃ and 350 ℃;
-desolventizing gas: 650L/h;
taper hole gas: 50L/h;
-scanning mode: multiple Reaction Monitoring (MRM),
the retention times and MRM parameters of the target compounds and internal standards are shown in table 4.
TABLE 4 retention times and MRM parameters for target compounds and internal standards
Figure SMS_8
4. Standard working curve production
The standard working solution (1.3.3) is measured according to the analysis condition of the instrument, and a standard working curve is established according to the peak area ratio and the content of the target compound and the internal standard substance. After each 20 sample measurements, a medium level of standard working solution should be added and if the measured value differs from the original value by more than 5%, the standard working curve should be re-made.
5. Sample measurement
The sample solution (2) was measured according to the instrument analysis conditions. Each sample was assayed in duplicate.
6. Calculation and expression of results
The target content in the nicotine formulation is calculated as follows.
Figure SMS_9
Wherein: x-the content of target in the aerosol in milligrams per gram (ug/g);
c-concentration of target in milligrams per milliliter (ug/mL) in sample solution;
v-volume of sample solution in milliliters (mL);
d-dilution factor;
m-mass of the atomized material, the unit is gram (g).
The arithmetic average of the two replicates was used as the final measurement.
7. Recovery rate, detection limit and quantification limit
The recovery, detection limit and quantitative limit of the method are shown in Table 5.
Table 5 method recovery, detection limit and quantitative limit
Sequence number Compounds of formula (I) Recovery% Detection limit ug/g Quantitative limit ug/g
1 Nicotine nitrogen oxides 96.3-103 10 30
2 Reduced nicotine 89.3-108.6 10 30
Drawings
Fig. 1: lactic acid structure 3D figure
Fig. 2: levulinic acid structure 3D map
Fig. 3: effect of different Nicotine salts on the atomizing Effect of Neotame
Fig. 4: reduced nicotine variant amount comparison chart of nicotine benzoate and nicotine lactate
Fig. 5: comparative graph of nitrogen oxide change of benzoic acid nicotine salt and lactic acid nicotine salt
Fig. 6: comparative graph of nitrogen oxide change of benzoic acid nicotine salt and levulinic acid nicotine salt
Fig. 7: effect of different content of ethyl butyrate on particle number concentration of nicotine benzoate salt atomized liquid aerosol
Fig. 8: effect of different content of ethyl butyrate on particle number concentration of nicotine lactate salt mist aerosol
Fig. 9: effect of different content of ethyl butyrate on the particle number concentration of atomized liquid aerosol of nicotine levulinate
Fig. 10: effect of different content of ethyl butyrate on particle number concentration of levulinic acid and lactic acid composite nicotine salt atomized liquid aerosol
Detailed Description
Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. While exemplary embodiments of the present disclosure are shown in the drawings, it should be understood that the present disclosure may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
Preparation of the nicotine salt and its preparation:
example 1: nicotine levulinate and preparation of preparation thereof
The base liquid referred to in this example was a mixed solvent of 1, 2-propanediol and glycerol in a ratio of 2:8 by weight.
To prepare an atomized solution of nicotine levulinate having a final nicotine content of 2% (w/w), the following procedure was applied to each of the atomized solutions of nicotine salts.
Example 1-1
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 60℃for 0.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.714g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to prepare a nicotine salt formulation.
Examples 1 to 2
The molar ratio of nicotine to levulinic acid is 1:0.5. 1.00g of nicotine and 0.358g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.642g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to prepare a nicotine salt formulation.
Examples 1 to 3
The molar ratio of nicotine to levulinic acid is 1:0.6. 1.00g of nicotine and 0.430g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.570g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to prepare a nicotine salt formulation.
Examples 1 to 4
The molar ratio of nicotine to levulinic acid is 1:0.7. 1.00g of nicotine and 0.502g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.498g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to prepare a nicotine salt formulation.
Examples 1 to 5
The molar ratio of nicotine to levulinic acid is 1:0.8. 1.00g of nicotine and 0.573g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.427g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to prepare a nicotine salt formulation.
Examples 1 to 6
The molar ratio of nicotine to levulinic acid is 1:0.9. 1.00g of nicotine and 0.644g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 48.356g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Example 2: nicotine lactate and preparation of its preparation
The base liquid referred to in this example was a mixed solvent of 1, 2-propanediol and glycerol in a ratio of 2:8 by weight.
To prepare an atomized solution of nicotine salt lactate having a final nicotine content of 1% (w/w), the following procedure was applied to each of the atomized solutions of nicotine salt.
Example 2-1
The molar ratio of nicotine to lactic acid is 1:1.1. 1.00g of nicotine and 0.611g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.389g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Example 2-2
The molar ratio of nicotine to lactic acid is 1:1.2. 1.00g of nicotine and 0.667g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 70℃for 2.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.333g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 3
The molar ratio of nicotine to lactic acid is 1:1.3. 1.00g of nicotine and 0.722g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 70℃for 2.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.278g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 4
The molar ratio of nicotine to lactic acid is 1:1.4. 1.00g of nicotine and 0.778g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.222g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 5
The molar ratio of nicotine to lactic acid is 1:1.5. 1.00g of nicotine and 0.833g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 70℃for 2.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.167g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 6
The molar ratio of nicotine to lactic acid is 1:1.6. 1.00g of nicotine and 0.944g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.056g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 7
The molar ratio of nicotine to lactic acid is 1:1.7. 1.00g of nicotine and 0.944g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.056g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 8
The molar ratio of nicotine to lactic acid is 1:1.8. 1.00g of nicotine and 1.000g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 98.000g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 9
The molar ratio of nicotine to lactic acid is 1:1.9. 1.00g of nicotine and 1.055g of lactic acid were added to a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 97.945g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 2 to 10
The molar ratio of nicotine to lactic acid is 1:2. 1.00g of nicotine and 1.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 2.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 97.889g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Example 3: levulinic acid and lactic acid composite nicotine salt and preparation of preparation thereof
The base liquid referred to in this example was a mixed solvent of 1, 2-propanediol and glycerol in a ratio of 2:8 by weight.
To prepare a complex nicotine salt nebulized solution having a final nicotine content of 4% (w/w), the following procedure was applied to each nicotine salt nebulized solution.
Example 3-1
The molar ratio of nicotine, levulinic acid and lactic acid is 1:0.5:0.5. a molar ratio of 1.000g of nicotine, 0.358g of levulinic acid and 0.278g of lactic acid was added to a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1 hour (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.364g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Example 3-2
The molar ratio of nicotine, levulinic acid and lactic acid is 1:0.6:0.5. 1.000g of nicotine, 0.430g of levulinic acid and 0.278g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1 hour (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.292g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 3
The molar ratio of nicotine, levulinic acid and lactic acid is 1:0.7:0.4. 1.000g of nicotine, 0.503g of levulinic acid and 0.222g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1 hour (magnetic stirring, 400 RPM) to obtain a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.275g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 4
The molar ratio of nicotine, levulinic acid and lactic acid is 1:0.8:0.2. 1.000g of nicotine, 0.574g of levulinic acid and 0.111g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 55℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.315g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 5
The molar ratio of nicotine, levulinic acid and lactic acid is 1:0.9:0.1. 1.000g of nicotine, 0.646g of levulinic acid and 0.056g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.298g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 6
The molar ratio of nicotine, levulinic acid and lactic acid is 1:1:0.2. 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.173g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 7
The molar ratio of nicotine, levulinic acid and lactic acid is 1:1.1:0.3. 1.000g of nicotine, 0.788g of levulinic acid and 0.167g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.045g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 8
The molar ratio of nicotine, levulinic acid and lactic acid is 1:1.2:0.2. 1.000g of nicotine, 0.859g of levulinic acid and 0.111g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 55℃for 2.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.030g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 9
The molar ratio of nicotine, levulinic acid and lactic acid is 1:1.2:0.3. 1.000g of nicotine, 0.859g of levulinic acid and 0.167g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.974g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 10
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:0.6, the molar ratio of levulinic acid to lactic acid is 12:1. 1.000g of nicotine, 0.397g of levulinic acid and 0.026g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.577g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 11
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:0.7, the molar ratio of levulinic acid to lactic acid is 11:1. 1.000g of nicotine, 0.459g of levulinic acid and 0.032g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.509g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 12
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:0.8, the molar ratio of levulinic acid to lactic acid is 8:1. 1.000g of nicotine, 0.509g of levulinic acid and 0.049g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.442g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 13
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:0.9, the molar ratio of levulinic acid to lactic acid is 10:1. 1.000g of nicotine, 0.586g of levulinic acid and 0.045g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.369g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 14
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:1.3, the molar ratio of levulinic acid to lactic acid is 7:1. 1.000g of nicotine, 0.815g of levulinic acid and 0.090g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 23.095g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 15
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:1.6, the molar ratio of levulinic acid to lactic acid is 3:1. 1.000g of nicotine, 0.859g of levulinic acid and 0.222g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.919g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 16
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:1.7, the molar ratio of levulinic acid to lactic acid is 2:1. 1.000g of nicotine, 0.812g of levulinic acid and 0.315g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.873g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 17
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:1.8, the molar ratio of levulinic acid to lactic acid is 8.5:1. 1.000g of nicotine, 1.153g of levulinic acid and 0.105g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.742g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 18
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:1.9, the molar ratio of levulinic acid to lactic acid is 5.6:1. 1.000g of nicotine, 1.154g of levulinic acid and 0.160g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.686g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Examples 3 to 19
The molar ratio of nicotine to mixed acid (levulinic acid and lactic acid) was 1:2, the molar ratio of levulinic acid to lactic acid is 11.5:1. 1.000g of nicotine, 1.318g of levulinic acid and 0.089g of lactic acid were charged into a 50mL eggplant-shaped flask, and after sealing, the mixture was stirred at 75℃for 1.5 hours (magnetic stirring, 400 RPM) to give a nicotine salt. After the nicotine salt was cooled to room temperature (20 ℃ -35 ℃) 22.593g of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved to give a nicotine salt formulation.
Preparation of atomized liquid of nicotine salt
Example 4: acetylpropionic acid nicotine salt atomized liquid
Example 4-1
The molar ratio of nicotine to levulinic acid is 1:0.8. 1.000g of nicotine and 0.573g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.427g (25 g of glycerin, 13.327g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) of the base solution was added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was obtained, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 4-2
The molar ratio of nicotine to levulinic acid is 1:0.6. 1.000g of nicotine and 0.430g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.57g (25 g of glycerin, 13.47g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) of a base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was obtained, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 4 to 3
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.714g (25 g of glycerin, 13.614g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Example 5: atomization liquid of lactic acid nicotine salt
Example 5-1
The molar ratio of nicotine to lactic acid is 1:0.8. 1.000g of nicotine and 0.444g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.556g (25 g of glycerin, 13.456g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Example 5-2
The molar ratio of nicotine to lactic acid is 1:1. 1.000g of nicotine and 0.556g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.444g (25 g of glycerin, 13.344g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Examples 5 to 3
The molar ratio of nicotine to lactic acid is 1:1.7. 1.000g of nicotine and 0.944g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.056g (25 g of glycerin, 12.956g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Examples 5 to 4
The molar ratio of nicotine to lactic acid was 1:1.2. 1.000g of nicotine and 0.667g of lactic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.333g (25 g of glycerin, 13.233g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Example 6: levulinic acid and lactic acid composite nicotine salt atomized liquid
Example 6-1
The molar ratio of nicotine to total acid is 1:0.8 (molar ratio of nicotine, levulinic acid and lactic acid is 1:0.5:0.3). 1.000g of nicotine, 0.358g of levulinic acid and 0.167g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a compound nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.475g (25 g of glycerin, 13.375g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) of base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid with a nicotine content of 2% (w/w).
Example 6-2
The molar ratio of nicotine to total acid is 1:1 (molar ratio of nicotine, levulinic acid and lactic acid 1:0.5:0.5). 1.000g of nicotine, 0.358g of levulinic acid and 0.278g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a compound nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.364g (25 g of glycerin, 12.264g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Examples 6 to 3
The molar ratio of nicotine to total acid is 1:1.7 (molar ratio of nicotine, levulinic acid and lactic acid is 1:1.2:0.5). 1.000g of nicotine, 0.859g of levulinic acid and 0.278g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a compound nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 47.863g (25 g of glycerin, 12.763g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Examples 6 to 4
The molar ratio of nicotine to total acid was 1:1.2 (molar ratio of nicotine, levulinic acid to lactic acid was 1:1:0.2). 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a levulinic acid+lactic acid complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.173g (25 g of glycerin, 13.073g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Example 7: acetylpropionic acid nicotine salt atomized liquid (containing ethyl butyrate)
Example 7-1: ethyl butyrate content 0.5%
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.25g of ethyl butyrate, 48.464g of (25 g of glycerin, 13.364g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 7-2: ethyl butyrate content 1%
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.5g of ethyl butyrate, 48.214g of (25 g of glycerin, 13.114g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 7-3: ethyl butyrate content 3%
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 1.5g of ethyl butyrate, 47.214g of (25 g of glycerin, 12.114g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 7 to 4: ethyl butyrate content 5%
The molar ratio of nicotine to levulinic acid is 1:0.4. 1.000g of nicotine and 0.286g of levulinic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine levulinate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 2.5g of ethyl butyrate, 46.214g of (25 g of glycerin, 11.114g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 8: atomization liquid of lactic acid nicotine salt (containing ethyl butyrate)
Example 8-1: ethyl butyrate content 0.5%
The molar ratio of nicotine to lactic acid was 1:1.2. 1.000g of nicotine and 0.667g of lactic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.25g of ethyl butyrate, 48.083g of (25 g of glycerin, 12.983g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 8-2: ethyl butyrate content 1%
The molar ratio of nicotine to lactic acid was 1:1.2. 1.000g of nicotine and 0.667g of lactic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.5g of ethyl butyrate, 47.833g of (25 g of glycerin, 12.733g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 8-3: ethyl butyrate content 3%
The molar ratio of nicotine to lactic acid was 1:1.2. 1.000g of nicotine and 0.667g of lactic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 1.5g of ethyl butyrate, 46.833g of (25 g of glycerin, 11.733g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 8 to 4: ethyl butyrate content 5%
The molar ratio of nicotine to lactic acid was 1:1.2. 1.000g of nicotine and 0.667g of lactic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine lactate salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 2.5g of ethyl butyrate, 45.833g of (25 g of glycerin, 10.733g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 9: levulinic acid and lactic acid compound nicotine salt atomized liquid (containing ethyl butyrate)
Example 9-1: ethyl butyrate content 0.5%
The molar ratio of nicotine to levulinic acid to lactic acid is 1:1:0.2. 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a levulinic acid+lactic acid complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.25g of ethyl butyrate, 47.923g of (25 g of glycerin, 12.823g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 9-2: ethyl butyrate content 1%
The molar ratio of nicotine to levulinic acid to lactic acid is 1:1:0.2. 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a levulinic acid+lactic acid complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.5g of ethyl butyrate, 47.673g of (25 g of glycerin, 12.573g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Example 9-3: ethyl butyrate content 3%
The molar ratio of nicotine to levulinic acid to lactic acid is 1:1:0.2. 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a levulinic acid+lactic acid complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 1.5g of ethyl butyrate, 46.673g of (25 g of glycerin, 11.573g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Examples 9 to 4: ethyl butyrate content 5%
The molar ratio of nicotine to levulinic acid to lactic acid is 1:1:0.2. 1.000g of nicotine, 0.716g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a levulinic acid+lactic acid complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 2.5g of ethyl butyrate, 45.673g of (25 g of glycerin, 10.573g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Comparative example 1: benzoic acid nicotine salt atomized liquid
Comparative examples 1 to 1
The molar ratio of nicotine to benzoic acid is 1:0.8. 1.000g of nicotine and 0.602g of benzoic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine benzoate. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.398g (25 g of glycerin, 13.298g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Comparative examples 1 to 2
The molar ratio of nicotine to benzoic acid is 1:1. 1.000g of nicotine and 0.753g of benzoic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain nicotine benzoate. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.247g (25 g of glycerin, 13.147g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Comparative examples 1 to 3
The molar ratio of nicotine to benzoic acid is 1:1.7. 1.000g of nicotine and 1.280g of benzoic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to give a nicotine benzoate. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 47.720g (25 g of glycerin, 12.62g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) of a base solution was added to the bottle, and the mixture was stirred for 10 minutes until a visually homogeneous solution was obtained, to obtain an atomized liquid having a nicotine content of 2% (w/w).
Comparative examples 1 to 4 (containing 0.5% of ethyl butyrate)
The molar ratio of nicotine to benzoic acid is 1:1. 1.000g of nicotine and 0.753g of benzoic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain nicotine benzoate. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 0.25g of ethyl butyrate, 47.997g of (25 g of glycerin, 12.897g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Comparative examples 1 to 5 (5% with ethyl butyrate)
The molar ratio of nicotine to benzoic acid is 1:1. 1.000g of nicotine and 0.753g of benzoic acid were put into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain nicotine benzoate. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 2.5g of ethyl butyrate, 45.747g of (25 g of glycerin, 10.647g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution were added to the flask, and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, giving an atomized liquid having a nicotine content of 2% (w/w).
Comparative example 2: benzoic acid-levulinic acid-lactic acid nicotine salt atomized liquid
Comparative example 2-1
The molar ratio of nicotine to total acid is 1:0.8 (molar ratio of nicotine to benzoic acid, levulinic acid and lactic acid is 1:0.5:0.1:0.2). 1.000g of nicotine, 0.377g of benzoic acid, 0.072g of levulinic acid and 0.111g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred (magnetic stirring, 400 RPM) at 65℃for 2 hours to obtain a complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.440g (25 g of glycerin, 13.340g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Comparative examples 2 to 2
The molar ratio of nicotine to total acid is 1:1 (molar ratio of nicotine to benzoic acid, levulinic acid, lactic acid is 1:0.5:0.1:0.4). 1.000g of nicotine, 0.377g of benzoic acid, 0.072g of levulinic acid and 0.222g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred (magnetic stirring, 400 RPM) at 65℃for 2 hours to obtain a complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 48.329g (25 g of glycerin, 13.229g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Comparative examples 2 to 3
The molar ratio of nicotine to total acid is 1:1.7 (molar ratio of nicotine to benzoic acid, levulinic acid and lactic acid is 1:1.2:0.1:0.4). 1.000g of nicotine, 0.904 of benzoic acid, 0.072g of levulinic acid and 0.222g of lactic acid were charged into a 100mL eggplant-shaped flask, and after sealing, the mixture was stirred at 65℃for 2 hours (magnetic stirring, 400 RPM) to obtain a complex nicotine salt. After cooling the nicotine salt to room temperature (20 ℃ C. -35 ℃ C.), 47.802g (25 g of glycerin, 12.702g of 1, 2-propanediol, 0.1g of neotame, 10g of orange essence) base solution was added to the bottle and the mixture was stirred for 10 minutes until a visually homogeneous solution was achieved, and an atomized liquid having a nicotine content of 2% (w/w) was obtained.
Sensory test evaluation experiment:
the electronic cigarette cartridges used in the test examples 1 and 2 are cotton core and net core heating wires (mainly iron chromium alloy), the test voltage is 4.14V (the marking voltage is 3.7V), and the test resistance is 1.4 omega.
Test example 1: effect of nicotine salt on fragrance extraction of a tobacco fragrance atomized liquid
Using the operating conditions of example 4-1 (stirring at 65 ℃ for 2h,400 rpm), benzoic acid, levulinic acid were formulated as nicotine salts with stoichiometric ratios of nicotine to levulinic acid of 1:0.3,1:0.4,1:0.6,1:0.9,1:1,1:1.2 and 1:1, respectively; adding tobacco flavor base solution (containing 1g of Yunyan extract, 40g of glycerol and 59g of 1, 2-propylene glycol) with the final nicotine content of 2% (w/w) to prepare an atomized liquid.
Smoke sensory evaluation criteria: comparison is made based on the degree of smoke aroma of the nicotine benzoate salt spray, as shown in table 6:
TABLE 6 sensory evaluation criteria for tobacco fragrance
Figure SMS_10
The tobacco aroma evaluation method comprises the following steps: 30 suction evaluation technical experts are selected, and each index is evaluated and sucked by the suction evaluation technical experts according to the sensory evaluation standards of the table 1.
And (3) calculating the evaluation result of the tobacco fragrance: the suction evaluation results of all suction evaluation technical experts are effective, the single suction evaluation results of all suction evaluation experts are calculated to be arithmetic average, and the result is reserved to one decimal, so that the total score is shown in table 7.
TABLE 7 evaluation results of tobacco fragrance
Figure SMS_11
Conclusion: from the evaluation results, when the stoichiometric amount of levulinic acid is less than 1 compared with nicotine, the smoke aroma of the atomized liquid is just stronger and more natural than that of the benzoic acid nicotine atomized liquid, particularly, the smoke aroma of the atomized liquid is 0.4-0.9 when the stoichiometric amount of levulinic acid is 0.4-0.6 when the stoichiometric amount of levulinic acid is compared with nicotine, more particularly, the smoke aroma of the atomized liquid is 0.6 when the stoichiometric amount of levulinic acid is compared with nicotine; however, when the stoichiometric amount of levulinic acid is greater than 1 compared with that of nicotine, the smoke flavor is affected, and particularly when the stoichiometric amount of levulinic acid and the stoichiometric amount of nicotine are 1:1 and 1:1.2, the atomized liquid has abrupt sour gas during sucking, and the smoke flavor feeling is seriously affected.
The inventor speculates that the benzoic acid vapor has strong irritation, and cough is easy to be caused after inhalation, and the experience of a smoker on smoke can be influenced, so that the benzoic acid vapor is not suitable for the electronic cigarette with the cigarette flavor; in addition, the inventor finds that the tobacco fragrance can be modified in a certain amount of levulinic acid, so that richer tobacco fragrance experience is brought to a smoker, but when the levulinic acid reaches a certain degree, the fruit sour taste of the levulinic acid can be suddenly released, and the fragrance of tobacco is influenced or covered.
Test example 2: effect of the Nicotine salt on the sweetness of an atomized liquid by suction
The invention objectively describes whether different acid-nicotine salts have influence on sweetness and how the sweetness is influenced by detecting the mass percentage concentration of neotame in the atomized liquid aerosol of examples 5 (5-1, 5-2, 5-3), 6 (6-1, 6-2, 6-3) and comparative examples 1 (1-1, 1-2, 1-3) and 2 (2-1, 2-2, 2-3).
The testing method comprises the following steps: the mass percent of neotame was calculated by testing the amount of neotame and the amount of solvent by the following formula.
Figure SMS_12
Test instrument:
test results: the amount of neotame and the amount of solvent (1, 2-propanediol, glycerol) in the suction port 50 were measured as shown in table 8;
TABLE 8 amount of neotame, solvent (1, 2-propanediol, glycerol)
Figure SMS_13
The mass percent change of neotame in other salt aerosols was calculated based on the mass fraction of neotame in the nicotine benzoate salt aerosol as shown in table 9, and the comparison graph is shown in fig. 3.
Table 9 variation of Neotame from nicotine benzoate salt nebulized aerosol
Figure SMS_14
The test evaluates the effect of different acid-nicotine salts on sweetness by testing the amount of neotame and solvent atomization in an atomized liquid containing the different acid-nicotine salts. From the test results, it can be seen that the lactic acid and/or levulinic acid nicotine salt has a better sweet feel by having a simultaneous effect on the amount of neotame and solvent atomization, resulting in an atomized liquid aerosol containing lactic acid and/or levulinic acid nicotine salt that contains more neotame than an atomized liquid aerosol containing benzoic acid nicotine salt.
Stability test evaluation experiment:
test example 3: effect of different acid nicotine salts on nornicotine
Nornicotine presents a health hazard to humans and is a synthetic precursor to the potential carcinogen nitrosonornicotine (NNN). The reduced nicotine is easy to generate in the preparation and storage processes, so that the quality of the smoke is deteriorated, and the safety of the electronic atomized liquid is influenced. The less nornicotine produced is better during the preparation of the nicotine salt.
The testing method comprises the following steps: 2.025g (99.95% purity) of nicotine and the corresponding stoichiometric amounts of acid (7 stoichiometric ratios of nicotine and benzoic acid test 1:0.4,1:0.6,1:1,1:1.2,1:1.6,1:2,1:2.5, respectively) were added to the eggplant flask, respectively, 7 stoichiometric ratios of nicotine and lactic acid test 1:0.4,1:0.6,1:1,1:1.2,1:1.6,1:2,1:2.5, respectively, were chosen, and the mixture was stirred (magnetic stirring, 400 RPM) at 65 ℃ for 2 hours after sealing, and the change in the total amount of nornicotine, "change in nornicotine = total amount of nornicotine in nicotine salt-total amount of nornicotine in nicotine used" was quantitatively detected).
Test results: as in fig. 4.
From the results, it can be seen that in the interval of 0.4-2 equivalents of acid, the use of lactic acid and nicotine co-heats, producing reduced nicotine less than benzoic acid; it is unexpected that when the amount of acid is greater than about 1.1 equivalent, the rate at which the "amount of nornicotine" decreases becomes greater as the amount of acid increases, the decrease being greater than that using benzoic acid. The results show that lactate in small amounts in the 0.4-1 equivalent range is also stable compared to benzoate in excess of benzoic acid in the 1-2 equivalent range, and the inventors speculate that lactate systems, in addition to providing the protons required for nicotine protonation, lend themselves to more stable such nicotine protonated forms and nicotine itself, reducing the likelihood of decomposition to nornicotine during nicotine salt production.
Test example 4: effect of different acid nicotine salts on nicotine nitrogen oxides
Nicotine oxynitride is one of the important indicators for detecting the degree of nicotine oxidation. The increase of the nicotine oxynitride not only can reduce the content of nicotine, but also has bad influence on the safety and the stability of the taste of the product.
The testing method comprises the following steps: 2.025g (99.95% purity) of nicotine and the corresponding stoichiometric acid (1:0.3, 1:0.4,1:0.6,1:1,1:1.2,1:1.6,1:2,1:2.5, respectively) were added to the respective stoichiometric nicotine and benzoic acid tests, 8 stoichiometric nicotine and lactic acid tests, 1:0.3,1:0.4,1:0.6,1:1,1:1.2,1:1.6,1:2,1:2.5, respectively, and 8 stoichiometric nicotine and levulinic acid tests, 1:0.3,1:0.4,1:0.6,1:1,1:1.2,1:1.6,1:2,1:2.5, respectively), the mixture was stirred (magnetic stirring, 400 RPM) at 65 ℃ for 2 hours after sealing, and the change in the total amount of oxynitride nicotine = total amount of the total nicotine-oxynitride was quantitatively detected in the total amount of the "total amount of oxynitride nicotine-nicotine salt".
Test results: the results are shown in FIGS. 5 and 6.
As can be seen from the results of FIG. 5, in the range of 0.4-2 equivalents of acid, co-heating lactic acid with nicotine produced less nicotine oxynitride than benzoic acid; it is unexpected that when the amount of acid is greater than about 1.1 equivalent, the rate at which the "amount of nornicotine" decreases becomes greater as the amount of acid increases, the decrease being greater than that using benzoic acid. The results show that lactate in small amounts in the 0.4-1 equivalent interval is also stable compared to benzoate in excess of benzoic acid in the 1-2 equivalent interval, and the inventors speculate that lactate systems may themselves make such nicotine protonated forms and nicotine itself more stable, reducing the potential for oxidation to oxynitride during nicotine salt preparation, in addition to providing the protons required for nicotine protonation.
From the results of fig. 6, it can be seen that the levulinic acid nicotine salt produces nicotine oxynitride in a relatively stable amount and in a much smaller amount than the benzoic acid nicotine salt, and the inventors speculate that one of the reasons that levulinic acid can make nicotine more stable should be related to its own structure, that levulinic acid has a long chain structure, that after providing protons to nicotine, it may more easily encapsulate the nicotine molecule, thereby possibly hindering oxygen ions from attacking the nicotine molecule, avoiding it to be oxidized, which makes the nicotine salt system more stable.
Particle size test of electronic smoke sol
Test example 5: analysis of the Effect of ethyl butyrate on aerosol particle size
The instrument used:
1. (Dongguan Feng) electronic atomizer smoke extractor (precision type)
2. (PALAS) DC10000 (dilution System)
3. (PALAS) U-SMPS/demc control lunit (universal scanning mobility particle sizer)
4. (PALAS) DEMC2000Column (differential electromobility classifier integrated with X-ray ionization)
5. (PALAS) UF-CPC50 (condensation particle counter)
6. The electronic cigarette bullet is cotton core and net core heating wire (mainly iron chromium alloy), the test voltage is 4.14V (marking voltage is 3.7V), and the test resistance is 1.4 omega.
7. The parameters of the electronic atomizer extractor are shown in Table 10:
table 10 parameters of electronic atomizer extractor
Figure SMS_15
The testing method comprises the following steps:
1. the test was performed on examples (4-3, 5-4, 6-4, 7-1, 7-2, 7-3, 7-4, 8-1, 8-2, 8-3, 8-4, 9-1, 9-2, 9-3, 9-4) and comparative examples (1-2, 1-4, 1-5) by injecting 6mL of the atomized liquid sample into 2 cartridges, respectively:
group I:
nicotine benzoate salt spray: comparative examples 1 to 2
Benzoic acid nicotinic salt atomized liquid+0.5wt% ethyl butyrate: comparative examples 1 to 4
Benzoic acid nicotinic salt atomized liquid+5% ethyl butyrate: comparative examples 1 to 5
Group II:
atomized solution of lactate nicotine salt: examples 5 to 4
The spray of the nicotine lactate salt is +0.5% ethyl butyrate: example 8-1
The spray of the nicotine lactate salt is +1% ethyl butyrate: example 8-2
The spray of the nicotine lactate salt is +3% ethyl butyrate: examples 8 to 3
Nicotinic lactate nebulization solution +5% ethyl butyrate: examples 8 to 4
Group III:
atomized liquid of levulinic acid nicotine salt: examples 4 to 3
The atomized solution of the levulinic acid nicotine salt is added with 0.5 percent of ethyl butyrate: example 7-1
Levulinic acid nicotinic salt atomized liquid+1% ethyl butyrate: example 7-2
Levulinic acid nicotinic salt atomized liquid+3% ethyl butyrate: examples 7 to 3
Levulinic acid nicotinic salt atomized liquid+5% ethyl butyrate: examples 7 to 4
Group IV:
levulinic acid and lactic acid composite nicotine salt atomized liquid: examples 6 to 4
Levulinic acid and lactic acid composite nicotine salt atomized liquid and 0.5% ethyl butyrate: example 9-1
Levulinic acid and lactic acid composite nicotine salt atomized liquid and ethyl butyrate accounting for 1 percent: example 9-2
Levulinic acid and lactic acid composite nicotine salt atomized liquid and 3% ethyl butyrate: examples 9 to 3
Levulinic acid and lactic acid composite nicotine salt atomized liquid and 5% ethyl butyrate: examples 9 to 4
2. The aerosol distribution of each group of samples was tested (3 times), stable, good reproducibility results were selected for comparison, particle number concentrations of small particle size aerosols (0.01 μm-0.06 μm) were selected for comparison, comparison results table 11, fig. 7 (group I), fig. 8 (group II), fig. 9 (group III), fig. 10 (group IV):
Table 11 results of particle count concentration test of electronic aerosol
Figure SMS_16
It is clear from Table 11 that there is little difference between the sample particle number concentration of 0.5%, or 1%, or 3%, or 5% ethyl butyrate from the addition of the atomized solution of nicotine benzoate in the range of small particle size aerosols (0.01 μm to 0.06 μm);
unexpectedly, the samples of the atomized solutions of nicotine levulinate, nicotine lactate and levulinate plus lactic acid complex were greatly varied, and the total amount of particle concentration reduction was 9760P/cm after the addition of 0.5% ethyl butyrate 3 ，15418P/cm 3 ，8229P/cm 3 . And the reduction of the particle number concentration of the sample is greatly increased along with the increase of the ethyl butyrate only in the atomized liquid of the nicotine levulinate and the atomized liquid of the nicotine lactate salt and the atomized liquid of the compound nicotine levulinate and the lactic acid.
The atomization liquid of the levulinic acid nicotine salt, the atomization liquid of the lactic acid nicotine salt and the atomization liquid of the levulinic acid and lactic acid compound nicotine salt are combined with 0.5 percent, or 1 percent, or 3 percent, or 5 percent of ethyl butyrate to greatly reduce the atomized aerosol with small particle size.
The concentration of small-particle-size particles of the electronic smoke sol is reduced, so that particles entering into deposited alveoli are greatly reduced, and the influence on the alveoli is reduced.
The present embodiment is merely illustrative of the present application and is not intended to be limiting, and those skilled in the art, after having read the present specification, may make modifications to the present embodiment without creative contribution as required, but is protected by patent laws within the scope of the claims of the present application.

Claims (25)

1. A nicotine salt formulation, wherein nicotine salt is prepared from lactic acid and nicotine in a molar ratio of (1.1-2): 1.
2. the nicotine salt formulation of claim 1, further comprising ethyl butyrate, the mass fraction of ethyl butyrate being 0% -5%.
3. The nicotine salt formulation of claim 1, further comprising a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
4. An electrospray solution comprising the nicotine salt formulation of any one of claims 1-3.
5. The electrospray solution of claim 4, the nicotine in the nicotine salt formulation having a concentration in the electrospray solution of greater than 0% w/w, less than 10% w/w.
6. The electronic atomized of claim 4, further comprising one or more of a sweetener, a cooling agent, and a flavoring.
7. An electronic cigarette cartridge comprising the electronic aerosol of any of claims 4-6.
8. The electronic cigarette cartridge of claim 7, further comprising an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
9. A nicotine salt formulation, wherein nicotine salt is prepared from an organic acid and nicotine, said organic acid consisting of levulinic acid and lactic acid, said levulinic acid to lactic acid molar ratio being from 12:1 to 1:1; the molar ratio of the organic acid to nicotine is from 0.6:1 to 2:1.
10. The nicotine salt formulation of claim 9, further comprising ethyl butyrate, the mass fraction of ethyl butyrate being 0% -5%.
11. The nicotine salt formulation of claim 9, further comprising a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
12. An electrospray liquid comprising the nicotine salt formulation of any one of claims 9-11.
13. The electrospray solution of claim 12, the nicotine in the nicotine salt formulation having a concentration in the electrospray solution of greater than 0% w/w, less than 10% w/w.
14. The electronic atomized liquid of claim 12 further comprising one or more of a sweetener, a cooling agent, and a flavoring.
15. An electronic cigarette cartridge comprising the electronic aerosol of any of claims 12-14.
16. The electronic cigarette cartridge of claim 15, further comprising an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
17. A nicotine salt formulation, wherein nicotine salt is prepared from levulinic acid and nicotine in a molar ratio of from 0.4:1 to 0.9:1.
18. the nicotine salt formulation of claim 17, further comprising ethyl butyrate, the mass fraction of ethyl butyrate being 0% -5%.
19. The nicotine salt formulation of claim 17, further comprising a solvent that is one or more of water, ethanol, 1, 2-propanediol, 1, 3-propanediol, glycerol, 1, 2-butanediol, 1, 3-butanediol, 1, 4-butanediol, 1,2, 3-butanetriol, 1,2, 4-butanetriol.
20. An electrospray liquid comprising the nicotine salt formulation of any one of claims 17-19.
21. The electrospray solution of claim 20, the nicotine in the nicotine salt formulation having a concentration in the electrospray solution of greater than 0% w/w, less than 10% w/w.
22. The electronic atomized liquid of claim 20 further comprising one or more of a sweetener, a cooling agent, and a flavoring.
23. An electronic cigarette cartridge comprising the electronic aerosol of any of claims 20-22.
24. The electronic cigarette cartridge of claim 23, further comprising an atomizing element that is a heated atomizing element or an ultrasonic atomizing element.
25. Use of a nicotine salt formulation according to any one of claims 1-3, 9-11, 17-19 in an electronic aerosol of tobacco, fruit or flower flavor.
CN202211676114.9A 2022-09-28 2022-12-26 Nicotine salt, atomized liquid, cartridge and application thereof Pending CN116268525A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022111928530 2022-09-28
CN202211192853 2022-09-28

Publications (1)

Publication Number Publication Date
CN116268525A true CN116268525A (en) 2023-06-23

Family

ID=86813798

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211676114.9A Pending CN116268525A (en) 2022-09-28 2022-12-26 Nicotine salt, atomized liquid, cartridge and application thereof

Country Status (2)

Country Link
CN (1) CN116268525A (en)
WO (1) WO2024066095A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382223B (en) * 2014-10-22 2017-03-15 浙江中烟工业有限责任公司 A kind of tobacco juice and electronic cigarette of the solvent and its preparation suitable for preparing Fruity type tobacco juice for electronic smoke
CN110250557A (en) * 2019-07-10 2019-09-20 四川领歌智谷科技有限公司 A kind of fragrant liquor electronic cigarette tobacco tar and preparation method thereof
CN110786538B (en) * 2019-09-03 2020-11-10 深圳昱朋科技有限公司 Nicotine formulation, preparation method thereof and electronic cigarette oil
EP3811789A1 (en) * 2019-10-24 2021-04-28 Nerudia Limited Smoking substitute system
CN111772225A (en) * 2020-07-08 2020-10-16 深圳市卓力能电子有限公司 Nicotine salt atomized liquid and preparation method thereof
GB202100353D0 (en) * 2021-01-12 2021-02-24 Ventus Medical Ltd Aerosolizable nicoltine-containing formulations
CN114983001A (en) * 2021-03-02 2022-09-02 深圳雾灵科技有限公司 Additive for tobacco products, preparation method and application thereof

Also Published As

Publication number Publication date
WO2024066095A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
Lindinger et al. Proton-transfer-reaction mass spectrometry (PTR–MS): on-line monitoring of volatile organic compounds at pptv levels
CN113038842B (en) Aerosol formulation
UA127838C2 (en) Aerosolisable formulation
KR20210119488A (en) water-based e-cigarette liquid
UA127723C2 (en) Aerosolisable formulation
CN108125277A (en) A kind of electronic cigarette and preparation method thereof
CN113358789A (en) Method for evaluating sensory contribution degree of tobacco monomer flavor in smoke
RU2770248C1 (en) Aerosol-forming composition
Bansal et al. Review of the analytical methods for and clinical impact of additives and flavors used in electronic cigarettes
Lu et al. Progress in quantification of nicotine content and form distribution in electronic cigarette liquids and aerosols
CN116268525A (en) Nicotine salt, atomized liquid, cartridge and application thereof
CN110495631B (en) Electronic cigarette liquid
CN111449270B (en) Smoke softener, electronic cigarette tobacco tar and preparation method thereof
JP7274514B2 (en) Aerosolizable formulation
CN112826125A (en) Flavor composition, electronic cigarette liquid and preparation method and application thereof
CN116548654B (en) Tobacco essence capable of reducing smoke stimulation and preparation method and application thereof
CN110558601A (en) Electronic cigarette liquid
CN107817195A (en) Particle size distribution measuring method of the electronic cigarette solution additive in flue gas aerosol
CN111296884A (en) Electronic cigarette liquid
CN114009825B (en) Electronic atomized liquid and atomization device comprising same
CN116120989B (en) Spice with sweet fruit flavor and compound flavor and preparation method and application thereof
CN108037045A (en) Heat the assay method that cigarette flavors are distributed in different-grain diameter flue gas aerosol that do not burn
Wylie Kinetics and Mechanisms of the Heterogeneous Ozonolysis of Tetrahydrocannabinol and Nicotine
CN108299359A (en) A kind of furans esters of gallic acid tobacco aromaticss and preparation method thereof and the application in cigarette
Anderson et al. A rapid quantitative screening method to assess chemicals present in heated e-liquids and e-cigarette aerosols

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination